Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6UXH8
UPID:
CCBE1_HUMAN
Alternative names:
Full of fluid protein homolog
Alternative UPACC:
Q6UXH8; Q6MZX5; Q86SS2; Q8TF19
Background:
Collagen and calcium-binding EGF domain-containing protein 1, also known as the Full of fluid protein homolog, plays a pivotal role in embryogenesis. It is essential for lymphangioblast budding and angiogenic sprouting from venous endothelium, highlighting its critical function in vascular development.
Therapeutic significance:
Given its involvement in Hennekam lymphangiectasia-lymphedema syndrome 1, a disorder characterized by lymph-vessel dysplasia, understanding the role of Collagen and calcium-binding EGF domain-containing protein 1 could open doors to potential therapeutic strategies.